Near-perfect adherence needed to suppress cell-associated HIV
Atazanavir/ritonavir more likely to cause kidney stones than other ritonavir-boosted protease inhibitors
Attachment inhibitor BMS-663068 does well in early study involving HIV-positive people
"Treatment partners" improve short-term virologic outcomes in those starting HIV therapy
Glucose metabolism worsens in HIV treatment-experienced taking NRTI-sparing regimens
Starting HIV treatment reduces risk of kidney disease
Three-quarters of clinicians in the US willing to prescribe early HIV treatment for the purpose of prevention
20 years of HIV Treatment Update
